Overview

Our History

Leadership Team

Partner

Portfolio Advisory Board

Peer Reviewed Publications

Announcements and Circulars

Listing Documents

Investor Presentation

IR Contact

Investor Calendar

Stock Information (2552.HK)

Corporate Communications

Media

Media Releases

Mar 11

2025

A Fresh Approach to Diabetes

Mar 11

2025

Interview of Li Chen - China Healthcare&LifeScience Review 2024

Oct 12

2021

Hua's diabetes therapy may be first to show clinical remission

Aug 24

2020

Hua teams up with Bayer for dorzagliatin as diabetes treatment in China

Aug 13

2020

China Healthcare Report 2020

Sep 18

2018

Hua’s Institutional Advantage

Jun 18

2018

Hua Medicine-on call to fight diabetes in China

May 08

2018

Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study

Jan 30

2018

Braced for the Biotech Boom

About Us

Overview

Our History

Leadership Team

Portfolio Advisory Board

Partner

Media center

Research & Development

Inovation

Dorzagliatin

mGluR5

Presentations

Peer Reviewed Publications

Media

Company News

Media Releases

Video

Investor Relations

Corporate Governance

Financial Report

Announcements & Circulars

Listing Documents

Investor Presentation

IR Contact

Investor Calendar

Stock information

Careers

Culture

Join Us

Products&Pipeline

Pipeline

HuaTangNing(华堂宁®)

Focus Us

沪公网安备 31011502013809号 Privacy Statement Terms of Use

How we use cookies

Hua Medicine uses cookies to enable and improve the use of the website. By continuing to use the site, you consent to the use of these cookies. To learn more about cookies, please read our privacy statement.